imatinib mesylate has been researched along with Parkinson Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brahmachari, S; Dawson, TM; Dawson, VL; Ge, P; Karuppagounder, SS; Ko, HS; Lee, S | 1 |
| Cowie, F; Grosset, DG; Watson-Fargie, T; White, J | 1 |
2 other study(ies) available for imatinib mesylate and Parkinson Disease
| Article | Year |
|---|---|
c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential.
Topics: Aging; alpha-Synuclein; Animals; Humans; Imatinib Mesylate; Oxidative Stress; Parkinson Disease; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl | 2017 |
Possible modulation of concurrent Parkinson's disease in the management of metastatic GIST: a review of two cases.
Topics: Aged; Antineoplastic Agents; Antiparkinson Agents; Carbidopa; Drug Combinations; Gastrectomy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Levodopa; Liver Neoplasms; Male; Parkinson Disease; Severity of Illness Index; Stomach Neoplasms | 2018 |